US PE Firms, Aurobindo Said to Eye Zentiva in €5 Billion Deal

US private equity firms GTCR and TPG Inc. are among funds considering bids for generic drugmaker Zentiva in a deal that could value the former Sanofi unit at about €5 billion ($5.9 billion), according to people familiar with the matter.

Indian drugmaker Aurobindo Pharma Ltd. is also weighing a bid for Zentiva, now owned by buyout firm Advent, the people said, asking not to be identified because the deliberations are private.

Talks are ongoing and no final decisions have been made, the people said, adding that other bidders could still emerge.

Representatives for TPG, Advent, Aurobindo and GTCR declined ...